<!DOCTYPE html>
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

<title>Objective(s)</title>

<script type="text/javascript">
window.onload = function() {
  var imgs = document.getElementsByTagName('img'), i, img;
  for (i = 0; i < imgs.length; i++) {
    img = imgs[i];
    // center an image if it is the only element of its parent
    if (img.parentElement.childElementCount === 1)
      img.parentElement.style.textAlign = 'center';
  }
};
</script>





<style type="text/css">
body, td {
   font-family: sans-serif;
   background-color: white;
   font-size: 13px;
}

body {
  max-width: 800px;
  margin: auto;
  padding: 1em;
  line-height: 20px;
}

tt, code, pre {
   font-family: 'DejaVu Sans Mono', 'Droid Sans Mono', 'Lucida Console', Consolas, Monaco, monospace;
}

h1 {
   font-size:2.2em;
}

h2 {
   font-size:1.8em;
}

h3 {
   font-size:1.4em;
}

h4 {
   font-size:1.0em;
}

h5 {
   font-size:0.9em;
}

h6 {
   font-size:0.8em;
}

a:visited {
   color: rgb(50%, 0%, 50%);
}

pre, img {
  max-width: 100%;
}
pre {
  overflow-x: auto;
}
pre code {
   display: block; padding: 0.5em;
}

code {
  font-size: 92%;
  border: 1px solid #ccc;
}

code[class] {
  background-color: #F8F8F8;
}

table, td, th {
  border: none;
}

blockquote {
   color:#666666;
   margin:0;
   padding-left: 1em;
   border-left: 0.5em #EEE solid;
}

hr {
   height: 0px;
   border-bottom: none;
   border-top-width: thin;
   border-top-style: dotted;
   border-top-color: #999999;
}

@media print {
   * {
      background: transparent !important;
      color: black !important;
      filter:none !important;
      -ms-filter: none !important;
   }

   body {
      font-size:12pt;
      max-width:100%;
   }

   a, a:visited {
      text-decoration: underline;
   }

   hr {
      visibility: hidden;
      page-break-before: always;
   }

   pre, blockquote {
      padding-right: 1em;
      page-break-inside: avoid;
   }

   tr, img {
      page-break-inside: avoid;
   }

   img {
      max-width: 100% !important;
   }

   @page :left {
      margin: 15mm 20mm 15mm 10mm;
   }

   @page :right {
      margin: 15mm 10mm 15mm 20mm;
   }

   p, h2, h3 {
      orphans: 3; widows: 3;
   }

   h2, h3 {
      page-break-after: avoid;
   }
}
</style>



</head>

<body>
<h1>Objective(s)</h1>

<p>The pharmacogenetic (PGx) study utilized data from this clinical study
and genome-wide germline genetic data to test for association between
genetic variants and differential efficacy response to [SPECIFY NAMES].</p>

<h1>Summary</h1>

<p>Of 20
subjects enrolled in the clinical study, a total of
19
(95%)
subjects provided PGx consent, a sample for genetic analysis and were
successfully genotyped.  For PGx analyses,
overlapping
treatment group(s) were defined as listed in Table 1.
Genotype-by-treatment interaction effects were estimated using
contrasts between main effects estimated independently for each
treatment group.</p>

<p>Table 1.  Disposition of subjects by PGx treatment group and availability of PGx data.</p>

<table><thead>
<tr>
<th align="left">group</th>
<th align="left">arms</th>
<th align="right">N.ITT</th>
<th align="right">N.PGx</th>
</tr>
</thead><tbody>
<tr>
<td align="left">Drug</td>
<td align="left">Drug</td>
<td align="right">11</td>
<td align="right">11</td>
</tr>
<tr>
<td align="left">Placebo</td>
<td align="left">Placebo</td>
<td align="right">9</td>
<td align="right">8</td>
</tr>
<tr>
<td align="left">All</td>
<td align="left">Drug (N=11), Placebo (N=9)</td>
<td align="right">20</td>
<td align="right">19</td>
</tr>
</tbody></table>

<p>Variables used in PGx analyses are summarized in Table 2.  For each
variable, the distribution in all ITT subjects, and in the PGx sample,
are compared, by treatment group.</p>

<p>Table 2.  Demographics of subjects included in PGx analyses.</p>

<table><thead>
<tr>
<th align="left"></th>
<th align="left">Drug, ITT</th>
<th align="left">Drug, PGx</th>
<th align="left">Placebo, ITT</th>
<th align="left">Placebo, PGx</th>
<th align="left">All, ITT</th>
<th align="left">All, PGx</th>
</tr>
</thead><tbody>
<tr>
<td align="left">N</td>
<td align="left">11</td>
<td align="left">11</td>
<td align="left">9</td>
<td align="left">8</td>
<td align="left">20</td>
<td align="left">19</td>
</tr>
<tr>
<td align="left">Randomized treatment, Drug, N (%)</td>
<td align="left">11 (100%)</td>
<td align="left">11 (100%)</td>
<td align="left">0 (0%)</td>
<td align="left">0 (0%)</td>
<td align="left">11 (55%)</td>
<td align="left">11 (58%)</td>
</tr>
<tr>
<td align="left">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.., Placebo, N (%)</td>
<td align="left">0 (0%)</td>
<td align="left">0 (0%)</td>
<td align="left">9 (100%)</td>
<td align="left">8 (100%)</td>
<td align="left">9 (45%)</td>
<td align="left">8 (42%)</td>
</tr>
<tr>
<td align="left">Sex, F, N (%)</td>
<td align="left">6 (55%)</td>
<td align="left">6 (55%)</td>
<td align="left">4 (44%)</td>
<td align="left">3 (38%)</td>
<td align="left">10 (50%)</td>
<td align="left">9 (47%)</td>
</tr>
<tr>
<td align="left">&hellip;, M, N (%)</td>
<td align="left">5 (45%)</td>
<td align="left">5 (45%)</td>
<td align="left">5 (56%)</td>
<td align="left">5 (62%)</td>
<td align="left">10 (50%)</td>
<td align="left">10 (53%)</td>
</tr>
<tr>
<td align="left">Age, Years, Mean (SD)</td>
<td align="left">35.18 (14.28)</td>
<td align="left">35.18 (14.28)</td>
<td align="left">35.00 (13.16)</td>
<td align="left">33.29 (13.21)</td>
<td align="left">35.11 (13.44)</td>
<td align="left">34.44 (13.51)</td>
</tr>
<tr>
<td align="left">&hellip;&hellip;&hellip;., Missing, N</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">1</td>
<td align="left">1</td>
<td align="left">1</td>
<td align="left">1</td>
</tr>
<tr>
<td align="left">Race, African, N (%)</td>
<td align="left">2 (18%)</td>
<td align="left">2 (18%)</td>
<td align="left">1 (11%)</td>
<td align="left">1 (12%)</td>
<td align="left">3 (15%)</td>
<td align="left">3 (16%)</td>
</tr>
<tr>
<td align="left">&hellip;., Asian, N (%)</td>
<td align="left">2 (18%)</td>
<td align="left">2 (18%)</td>
<td align="left">0 (0%)</td>
<td align="left">0 (0%)</td>
<td align="left">2 (10%)</td>
<td align="left">2 (11%)</td>
</tr>
<tr>
<td align="left">&hellip;., Mixed, N (%)</td>
<td align="left">0 (0%)</td>
<td align="left">0 (0%)</td>
<td align="left">1 (11%)</td>
<td align="left">0 (0%)</td>
<td align="left">1 (5%)</td>
<td align="left">0 (0%)</td>
</tr>
<tr>
<td align="left">&hellip;., White, N (%)</td>
<td align="left">7 (64%)</td>
<td align="left">7 (64%)</td>
<td align="left">7 (78%)</td>
<td align="left">7 (88%)</td>
<td align="left">14 (70%)</td>
<td align="left">14 (74%)</td>
</tr>
<tr>
<td align="left">Ethnicity, Hispanic, N (%)</td>
<td align="left">3 (27%)</td>
<td align="left">3 (27%)</td>
<td align="left">1 (11%)</td>
<td align="left">0 (0%)</td>
<td align="left">4 (20%)</td>
<td align="left">3 (16%)</td>
</tr>
<tr>
<td align="left">&hellip;&hellip;&hellip;, Not Hispanic, N (%)</td>
<td align="left">8 (73%)</td>
<td align="left">8 (73%)</td>
<td align="left">8 (89%)</td>
<td align="left">8 (100%)</td>
<td align="left">16 (80%)</td>
<td align="left">16 (84%)</td>
</tr>
<tr>
<td align="left">log10ALT, xULN, maximun on treatment, Mean (SD)</td>
<td align="left">-0.00 (0.22)</td>
<td align="left">-0.00 (0.22)</td>
<td align="left">-0.04 (0.19)</td>
<td align="left">-0.01 (0.17)</td>
<td align="left">-0.02 (0.20)</td>
<td align="left">-0.01 (0.20)</td>
</tr>
<tr>
<td align="left">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;, Missing, N</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">ALT, xULN, baseline, Mean (SD)</td>
<td align="left">0.79 (0.47)</td>
<td align="left">0.79 (0.47)</td>
<td align="left">0.62 (0.36)</td>
<td align="left">0.67 (0.34)</td>
<td align="left">0.71 (0.42)</td>
<td align="left">0.74 (0.41)</td>
</tr>
<tr>
<td align="left">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;., Missing, N</td>
<td align="left">1</td>
<td align="left">1</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">1</td>
<td align="left">1</td>
</tr>
<tr>
<td align="left">ALT cases and controls, Mean (SD)</td>
<td align="left">0.00 (0.00)</td>
<td align="left">0.00 (0.00)</td>
<td align="left">0.00 (0.00)</td>
<td align="left">0.00 (0.00)</td>
<td align="left">0.00 (0.00)</td>
<td align="left">0.00 (0.00)</td>
</tr>
<tr>
<td align="left">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;., Missing, N</td>
<td align="left">7</td>
<td align="left">7</td>
<td align="left">5</td>
<td align="left">5</td>
<td align="left">12</td>
<td align="left">12</td>
</tr>
<tr>
<td align="left">Survival, months, Mean (SD)</td>
<td align="left">13.45 (7.27)</td>
<td align="left">13.45 (7.27)</td>
<td align="left">11.78 (6.92)</td>
<td align="left">11.25 (7.21)</td>
<td align="left">12.70 (6.98)</td>
<td align="left">12.53 (7.13)</td>
</tr>
<tr>
<td align="left">&hellip;&hellip;&hellip;&hellip;&hellip;., Missing, N</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">Censoring flag for survival code, 0 for censor, 1 for event, Mean (SD)</td>
<td align="left">0.45 (0.52)</td>
<td align="left">0.45 (0.52)</td>
<td align="left">0.44 (0.53)</td>
<td align="left">0.50 (0.53)</td>
<td align="left">0.45 (0.51)</td>
<td align="left">0.47 (0.51)</td>
</tr>
<tr>
<td align="left">&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.., Missing, N</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">pop.PNITT, N</td>
<td align="left">11</td>
<td align="left">11</td>
<td align="left">9</td>
<td align="left">8</td>
<td align="left">20</td>
<td align="left">19</td>
</tr>
<tr>
<td align="left">is.PGx, N</td>
<td align="left">11</td>
<td align="left">11</td>
<td align="left">8</td>
<td align="left">8</td>
<td align="left">19</td>
<td align="left">19</td>
</tr>
</tbody></table>

<ul>
<li>[VARIABLE] was inverse normal transformed prior to association analysis. ** [VARIABLE] was derived by [insert brief summary].
[IF NECESSARY COMMENT ON ANY GROSS IMBALANCES (see hidden text above for guidance)]</li>
</ul>

<p>PGx analyses conducted are summarized in Table 3.  The specific
candidate genetic variants (CG) analysed are listed in Appendix Table
1.  The number of significantly associated variants are summarised in
total for each analysis.
 
Table 3.  PGx analysis summary</p>

<table><thead>
<tr>
<th align="left">model</th>
<th align="left">group</th>
<th align="left">lambda</th>
<th align="left">thresh1</th>
<th align="left">hits1</th>
<th align="left">thresh2</th>
<th align="left">hits2</th>
</tr>
</thead><tbody>
<tr>
<td align="left">Baseline</td>
<td align="left">All</td>
<td align="left">0.494</td>
<td align="left">2.50e-08</td>
<td align="left">0/895</td>
<td align="left">2.27e-03</td>
<td align="left">0/6</td>
</tr>
<tr>
<td align="left">SafetyQTA1</td>
<td align="left">Placebo</td>
<td align="left">1.234</td>
<td align="left">8.33e-09</td>
<td align="left">0/741</td>
<td align="left">7.58e-04</td>
<td align="left">0/3</td>
</tr>
<tr>
<td align="left">SafetyQTA1</td>
<td align="left">Drug</td>
<td align="left">0.721</td>
<td align="left">8.33e-09</td>
<td align="left">0/812</td>
<td align="left">7.58e-04</td>
<td align="left">0/5</td>
</tr>
<tr>
<td align="left">SafetyQTA1</td>
<td align="left">Drug/Placebo</td>
<td align="left">0.880</td>
<td align="left">8.33e-09</td>
<td align="left">0/606</td>
<td align="left">7.58e-04</td>
<td align="left">0/2</td>
</tr>
<tr>
<td align="left">SafetyQTA2</td>
<td align="left">Drug</td>
<td align="left">1.353</td>
<td align="left">1.25e-08</td>
<td align="left">0/801</td>
<td align="left">1.14e-03</td>
<td align="left">0/5</td>
</tr>
<tr>
<td align="left">SafetyQTA2</td>
<td align="left">Drug/Placebo</td>
<td align="left">0.926</td>
<td align="left">1.25e-08</td>
<td align="left">10/579</td>
<td align="left">1.14e-03</td>
<td align="left">0/2</td>
</tr>
<tr>
<td align="left">SafetyCC</td>
<td align="left">Drug</td>
<td align="left">0.000</td>
<td align="left">8.33e-09</td>
<td align="left">0/642</td>
<td align="left">7.58e-04</td>
<td align="left">0/5</td>
</tr>
<tr>
<td align="left">SafetyCC</td>
<td align="left">Drug/Placebo</td>
<td align="left">0.000</td>
<td align="left">8.33e-09</td>
<td align="left">0/372</td>
<td align="left">7.58e-04</td>
<td align="left">0/1</td>
</tr>
<tr>
<td align="left">SafetyCC</td>
<td align="left">Drug/All</td>
<td align="left">0.000</td>
<td align="left">8.33e-09</td>
<td align="left">0/604</td>
<td align="left">7.58e-04</td>
<td align="left">0/5</td>
</tr>
<tr>
<td align="left">Efficacy1</td>
<td align="left">Drug/Placebo</td>
<td align="left">1.106</td>
<td align="left">2.50e-08</td>
<td align="left">0/606</td>
<td align="left">2.27e-03</td>
<td align="left">0/2</td>
</tr>
<tr>
<td align="left">Efficacy2</td>
<td align="left">Drug</td>
<td align="left">3.517</td>
<td align="left">1.25e-08</td>
<td align="left">0/817</td>
<td align="left">1.14e-03</td>
<td align="left">0/10</td>
</tr>
<tr>
<td align="left">Efficacy2</td>
<td align="left">Drug/Placebo</td>
<td align="left">0.067</td>
<td align="left">1.25e-08</td>
<td align="left">0/591</td>
<td align="left">1.14e-03</td>
<td align="left">0/5</td>
</tr>
</tbody></table>

<ul>
<li>All analyses (whether with or without baseline clinical covariates)
were adjusted for [number of] ancestry principal components to control
for confounding by population structure (Price et al. 2006).  [If
needed:] All analyses for Treatment Group 3 were additionally adjusted
for study arm.  ** The genomic control coefficient λ, estimated from
the genome-wide association scan (GWAS) results for each
analysis/covariate/treatment group combination, provides a measure of
test statistic calibration after covariate adjustment (expected value
λ=1), and any residual test statistic inflation was corrected using
the genomic control method (Devlin et al. 2001).</li>
</ul>

<h1>Conclusions</h1>

<p>None of the genetic variants investigated (neither GWAS nor candidate
genetic variants), were significantly associated with any of the
[EFFICACY and/or SAFETY] endpoint(s) investigated.</p>

<h1>Appendix</h1>

</body>

</html>
